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Abstract
Background: We aimed to examine the burden of intrahepatic cholangiocarcinoma (ICC) in Thailand and identify
the prognostic factors for all-causes of death.
Methods: We conducted a population-based study of ICC patients admitted during 2009–2013 using the Nationwide
Hospital Admission Database, the National Health Security Office (NHSO). There was an average of 1,051,146 patients/
year with diagnosis of gastrointestinal diseases (GI). All patients with a diagnosis of ICC (ICD10- C221) were
included from a total of 72,479 admissions from 858 hospitals. The surgical resection procedures such as the
radical pancreaticoduodenectomy, subtotal and partial hepatectomy were analyzed. Data for all patients were
censored 1 year post-study or death, whichever came first.
Results: A total of 34,325 patients with ICC during a 5-year study period (on average, 6865 patients/year, with
the incidence rate of 14.6 per 100,000 population, per year. The ICC patients had a mean age of 63.8+/−11.
6 years and 63% were males. The mean length of hospital stay was 6.4+/−7.3 days with a mean+/−SD cost of
hospitalization of $595+/−$1160 USD per admission. There were 659 patients (1.9%) underwent surgical
resection. The overall survival of ICC patients with surgery was significantly better than those patients without
surgery. Hazard ratio of death for patients without surgery was 2.5 (95% CI of 2.3–2.7). Approximately 14% of
the ICC patients died during hospitalization. The median overall survival of all patients after the first admission
was 53 +/−0.6 days. From the multivariate analysis, factors related to all-causes of death were: patients’ age
>60 years (OR = 1.2, 95% CI; 1.1–1.3), length of hospital stay of >7 days (OR = 1.1, 95% CI; 1.02–1.2), male (OR = 1.3, 95%
CI; 1.2–1.4), living in the northern part of Thailand (OR = 1.5, 95% CI; 1.3–1.8) and presence of complications during
admission (OR = 1.3, 95% CI; 1.1–1.5).
Conclusion: The disease burden of patients with ICC in Thailand is significant with the incidence rate of 14.6 per
100,000 population, per year during 2009–2013 and showed high mortality rate of 14%.
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Background
Cholangiocarcinoma is one of the major liver cancers in
Asia caused by parasites such as Opisthorchis viverrini
and Clonorchis sinensis [1]. In 2008, it has been reported
that the relative risk for cholangiocarcinoma with O
viverrini is 7.7 and is prevalent in Southeast Asian coun-
tries [2]. Other contributing risk factors are hepatolithia-
sis, primary sclerosing cholangitis, chronic viral hepatitis
B and C, cirrhosis, diabetes, obesity and Caroli’s disease
[3]. Thailand has reported a high incidence of cholangio-
carcinoma, especially in the KhonKaen Province, and is
more prevalent in men than in women with an inci-
dence of 84.6 vs. 36.8 per 100,000 persons per year, re-
spectively [4].
The current staging of cholangiocarcinoma is based on
the anatomical obstruction and location, and divided
into 2 groups: extrahepatic (80%) and intrahepatic chol-
angiocarcinoma (20%) [3]. Intrahepatic cholangiocarci-
noma (ICC) was classified and prognosed according to
the number of tumors present, its differentiation, lymph
node metastases and vascular invasion [5] whereas ex-
trahepatic cholangiocarcinoma is classified as perihilar
cholangiocarcinoma, Klatskin tumor or distal common
bile duct cholangiocarcinoma [6] Recently, the Mayo
clinic group proposed a new staging system based on
the size and number of the tumor, vascular invasion and
performance status which also showed that the median
survivals of patients with perihilar-cholangiocarcinoma
stages 1–4 varied from 48, 22, 8.6 and 3 months re-
spectively [6]. This new Mayo clinical staging system is
better than the TNM classification system which was
based on histopathological findings in predicting the
survival outcome of patients with perihilar cholangio-
carcinoma [3, 6].
Current and novel therapies, including surgical or
endoscopic treatment with neoadjuvant chemo-radiation
therapy, may improve the survival in patients with cer-
tain cholangiocarcinoma stages [5, 7]. The intrahepatic
cholangiocarcinoma (ICC) had the highest incidence in
Asia [8], however the definite cause remains unclear.
Additionally, ICC is associated with a high rate of fatality
because of its nature of early invasion, widespread me-
tastasis, and lack of effective treatment [9]. The median
survival for Thai patients with advanced stages of cholan-
giocarcinoma was 5–6 months with palliative care [10].
However, cholangiocarcinoma patients with stages 3–4 had
a higher mortality rate than those with stages 1–2 by 6.8
folds [11]. Yet there is a lack of data on the burden and out-
come of ICC from the country with high prevalence of dis-
ease. The data reported from the previous studies were
obtained from different hospital-based databases so the
authors worked with the government to examine the bur-
den of ICC in the country, and identify the prognostic
factors for all causes of death of patients with ICC.
Methods
Study design
Thailand adopted a universal public health care system
in 2002, which is comprised of three national health
insurance categories: Civil Servant Medical Benefit
Scheme (CSMBS), Social Security Scheme (SSS) and
Medical Welfare Scheme (MWFS). CSMBS includes all
civil servant officers with close family which individu-
ally reimburses medical expenses from the Controller
General’s Department. SSS includes all Thai employees
who are registered to the National Social Security Fund.
MWFS includes all the remaining Thai citizens in the
national database, which can access public health ser-
vices from public hospitals and private hospital regis-
tered with The National Health Security Office
(NHSO). NHSO database is the data from main univer-
sal public health care system in Thailand since 2002
which includes more than 80% of the population and
more than 90% of all admissions from most public
hospitals and some private hospitals in Thailand.
Therefore, we conducted a population-based cohort
study of ICC patients in Medical Welfare Scheme from
2009 to 2013 using the government’s health care data-
base, the NHSO, Thailand. There was an average of
1,051,146 patients/year or 1,365,557 admissions/year
with diagnosis of gastrointestinal diseases (GI). All pa-
tients with a diagnosis of ICC (ICD10- C221) were in-
cluded from a total of 72,479 admissions from 858
hospitals. All patients were assessing the survival status
until September 2014 using death registration.
Study population
All ICC patients included in the study were more than
19 years old. The patient baseline characteristics and
clinical outcomes were obtained from the patients’ main
health insurance schemes of Medical Welfare Scheme.
From the NHSO database, which mainly focus on the
cost of hospitalization based on the diagnosis or
diagnosis-related group (DRG). We extracted the follow-
ing variables: the number of hospitalizations, mortality
rate, complications, length of hospital stay, co-morbidity
and the medical expenses per hospitalization.
Inclusion criteria
From the annual rate of the overall hospitalization of
5,658,937 admissions, there was an average of 1,365,557
admissions per year from GI diseases which accounted
for 24% of the overall hospitalization annually. We in-
cluded all patients with primary diagnosis of ICC from
72,479 admissions during the 5-year period. (The details
of the total annual hospitalization and the number of
hospitalization from GI diseases based on ICD codes
were reported in Additional file 1: Tables S1–S2).
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The reported frequency of ICC for 2009 was 15.9%,
for 2010 was 19.2%, for 2011 was 19.4%, for 2012 was
21.8% and for 2013 was 23.8%. The NHSO provided us
access to the data from the Nationwide Hospital Admis-
sion Database.
Definitions
The diagnosis of ICC, co-morbidities and complications
were based on the International Statistical Classification
of Diseases and Related Health Problems 10th Revision
(ICD-10).
Co-morbidities and complications were identified by the
following medical codes: coronary artery heart disease
(CAD)-I251; congestive heart failure (CHF)-I500; chronic
kidney disease (CKD) stages 1–5 -N181-N185; chronic
obstructive pulmonary disease (COPD), unspecified-
J449; history of stroke, not specified as hemorrhage or
infarction-I64; diabetes mellitus (DM)- E149; sepsis-
A419; ICD9 procedure; renal failure requiring dialysis-
PRO3995; respiratory failure requiring ventilation for
less than 96 consecutive hours-PRO9671; respiratory fail-
ure requiring ventilation for more than 96 consecutive
hours-PRO9672; and infected wound surgical-T814.
Operable case with ICC was defined as a patient who
underwent surgical resection procedure such as radical
pancreaticoduodenectomy (procedure ICD9 CM 527),
subtotal (procedure ICD9 CM 504) or partial hepatec-
tomy (procedure ICD9 CM 5022).
The outcome measurements were the mortality rate, the
proportion of complications, the length of hospital stay
and the factors influencing mortality rate. Death was de-
fined as all-causes of death from 2009 to September 28,
2014.
Statistical analyses
The patients were categorized into 2 groups according
to their treatment options: surgical and non-surgical
groups. Patients in the surgical group were operable
cases and defined as those ICC patients who underwent
the surgical resection procedures such as radical pan-
creaticoduodenectomy, subtotal or partial hepatectomy.
For the non-surgical group, these patients received non-
surgical treatment. The differences between the 2 groups
were compared by using student t test for continuous
variables and were tested by the Chi-square test for pro-
portions. Continuous outcomes are presented as the
mean ± standard deviation (SD), and categorical data are
presented as numbers (percentage). In this study, two-
sided P- values <0.05 were considered statistically sig-
nificant. This study used the SPSS statistical software
package (SPSS Version 13) for analysis. The study was
approved by the Institutional Review Board (IRB 113/58;
Apr27, 2015) of the Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand.
Results
Baseline characteristics and the burden of ICC in Thailand
From a total of 72,479 hospitalization with diagnosis of
ICC based on ICD-221, there were 34,325 patients dur-
ing the 5-year study period (on average, 6865 patients/
year). The number of registration of Thai people in the
NHSO system comprise of 47,000,000 people which is
the majority group (67.6%) of the population of Thailand
in 2013 which is 69.52 million people. Based on this
number, the incidence rate of 14.6 per 100,000 popula-
tion, per year (details in Additional file 1: Table S2). The
mean age was 63.8+/−11.6 years. 63% were males. Over-
all cases of ICC were geographically distributed nation-
wide with predominant in northeastern part Thailand.
The baseline characteristics and their comorbidities are
shown in Table 1. The mean length of hospital stay was
5.7+/−6.9 days with a mean+/−SD cost of hospitalization
Table 1 The baseline characteristics and comorbidities of the
overall admissions of ICC patients from 2009 to 2013
Variables ICC patients
(n = 72,749 admission)
Age (mean+/− SD) 63.79 +/−11.59
- Age >60-year, n (%) 61.6%
Sex (%male) 63.2%
Hospital (H) level; %
- Community H. 76.6%
- General H. 14.5%
- Tertiary care H. 5.1%
- Private H. 0.9%
- others (NHSO, no data) 2.9%







- Atherosclerotic heart disease 0.1%
- Congestive heart failure 0.5%
- COPD 0.9%
- Diabetes Mellitus 0.2%
- Stroke 0.1%
- Chronic kidney disease 0.4%
- Cirrhosis 2.7%
- Viral Hepatitis B 0.4%
- Viral Hepatitis C 0.3%
- HIV infection 0.2%
Note: COPD chronic obstructive pulmonary disease
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of US$595+/−1160 USD per admission (exchange rate
35.62 baht/US dollar).
Treatment outcomes and prediction of mortality
There were 659 ICC patients (1.9%) who had resec-
tioned surgery such as radical pancreaticoduodenect-
omy (n = 55), subtotal (n = 79) or partial hepatectomy
(n = 525). Treatment outcomes for patients with sur-
gery were significantly better than those without
surgery are shown in Fig. 1. The overall survival of pa-
tients with surgery was significantly better than those
patients without surgery. Figure 2 and Table 2 show
the hazard ratio of death for patients without surgery
which was 2.5 (95% CI of 2.3–2.7). There was no sig-
nificant difference of survival time among the 3 differ-
ent procedures (radical pancreaticoduodenectomy,
subtotal or partial hepatectomy).
From 34,325 patients ICC patients, 4777 patients
died during the follow-up period. The all-cause mor-
tality rate was 14%. The median overall survival for all
patients after first admission was 53 +/−0.6 days (95%
CI 51.7–54.3). The hazard ratio of death in patients
without surgery was 2.5 (95% CI of 2.3–2.7). From the
multivariate analysis, factors related to all causes of
death were the patients’ age >60 years (OR = 1.2, 95%
CI; 1.1–1.3), length of hospital stay (LOS) of >7 days
(OR = 1.1, 95% CI; 1.02–1.2), male (OR = 1.3, 95% CI;
1.2–1.4), living in the northern part of Thailand (OR =
1.5, 95% CI; 1.3–1.8) and presence of complications
during admission (OR = 1.3, 95% CI; 1.1-1.5). In
addition, we found that the ICC patients who had LOS
≤7 days had significantly lower frequency of comorbid-
ities including atherosclerotic heart disease , congest-
ive heart failure, cirrhosis, viral hepatitis B viral
hepatitis C and HIV infection than those with LOS
>7 days (p <0.05) (Additional file 1: Table S3).
Discussion
In the current study, the incidence rate of 14.6 per
100,000 population, per year with mortality rate of 14%.
This NHSO database is nationwide study, and its cover-
age of at least of 67.6% of the population of Thailand in
2013 and this database were used and validate in several
studies including disease burden of cirrhosis, drug in-
duced liver injury and liver abscess [12–14]. Most of
ICC patients presented with advanced stages by their
clinical findings and complications. Due to the limited
Fig. 1 Mean overall survival of all patients with intrahepatic cholangiocarcinoma after first admission
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information of clinical staging, however in our study we
had only 1.9% of ICC patients underwent surgical treat-
ment. The new classification of advanced stage cholan-
giocarcinoma by the Mayo clinic group [6] mentioned
that the TNM staging system is used to predict the dis-
ease outcome, which is mainly based on the histopatho-
logical information from the operation. Thus, the TNM
staging cannot applied to the patients with ICC because
most of them have unresectable disease which is sup-
ported by our data and it was similar to previous studies
from Thailand [10, 11, 15, 16]. Our study demonstrated
that several factors predicted poor survival outcome of
hospitalized ICC patients included advanced age
>60 years, length of hospital stay of >7 days which re-
lated to the more frequency of comorbidities, male, liv-
ing in the northern part of Thailand, and presence of
complications during admission. In addition, the tumor
size of at least 5 cm and the regional lymph node metas-
tasis were reported as key predictors of higher chance of
perineural or vacular invasion [17]. This important in-
formation regarding to the ICC characteristics including
the size of tumor and histopathology were lacking in our
database thus we cannot add this variables into our ana-
lysis. One of the major reason of poor outcomes of ICC
patients in Thailand is the lacking of early diagnosis.
The heterogeneous of tumor biology, risk factors and
Fig. 2 Mean overall survival for all patients with intrahepatic cholangiocarcinoma with surgery compared to those without surgery
Table 2 The survival outcome of patients with intrahepatic
cholangiocarcinoma classified by the type of surgical treatment
Univariate Cox regression
Type of surgery Crude
hazard ratio
95% CI p-value
Radical pancreaticoduodenectomy 2.2 1.61–3.04 <0.001
Subtotal hepatectomy. 2.6 1.98–3.43 <0.001
Partial hepatectomy. 2.5 2.22–2.72 <0.001
Presence of any one of three
surgical treatment options
2.5 2.25–2.70 <0.001
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clinical features may be the reasons for the difficulty of
developing surveillance measures in high risk group
[18, 19]. Our data of disease burden of ICC with high
mortality rate of 14%. as well as low proportion of ICC
patients underwent surgical treatment (1.9%) may be
useful for the health care policy makers and the clini-
cians to consider for implement health care policy or
setting up the surveillance measures in other centers.
The main strength of this study is the fact that we had
access to the nation’s health care database, Nationwide
Hospital Admission Database, so was able to assess the
disease burden of ICC with the incidence rate of 14.6
per 100,000 population, per year during 2009–2013.
Even though, there is limited information in clinical
findings but the burden of intrahepatic cholangiocarci-
noma which has high mortality rate and most of them
present as non-operable stage are valuable for national
health care policy planning for early stage of cancer de-
tection. The average costs of hospitalization of the GI
and liver related diseases in Thailand during 2009–2013
are lower than those reported in the United States [20]
(Additional file 1: Table S4). However, there are some
limitations. First, there was not enough information in
regards to the major risk factors and staging of ICC devel-
opment, such as liver flukes. This limitation was explained
by the design of the nationwide database which focused
on financial purpose of reimbursement, no for clinical
data collection. Second, the parameters outside of the
Nationwide Hospital Admission Database including the
clinical information, the blood tests were not collected.
Conclusions
The disease burden of patients with ICC in Thailand is
significant with the incidence rate of 14.6 per 100,000
population, per year and showed high mortality rate of
14%. The health promotion and prevention as well as
the early stage of ICC detection may be a relevant strat-
egy in developing countries.
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the National Health Security Office (NHSO), Thailand, showed an average
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patients with diagnosis of ICC based on ICD-221 (N = 72,479 admissions)
during the 5-year period. Table S3. Comparison ICC patients who had
length of hospital stay (LOS) ≤7 days and those with LOS >7 days. Table S4.
The average cost of hospitalization and the in-hospital mortality rate
classified by disease; during 2009–2013 from the Nationwide Hospital
Admission Data of Thailand. (DOCX 20 kb)
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